Capital increase in Lundbeck as a result of employee warrant programme and buy-back of shares to fund Long-Term Incentive scheme
- Lundbeck increases its share capital by 593 shares (less than 0.01% of outstanding shares) as a result of employee warrant exercise
H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 2,965, as a consequence of the exercise of employee warrants.
The increase is affected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 593 shares at DKK 102. Proceeds to the company are DKK 60,486.00 (approximately USD 10,400). The increase corresponds to approximately 0.0003% of the company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2012. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Commerce and Companies Agency. Lundbeck's current share capital amounts to DKK 980,679,590 and will after the capital increase be DKK 980,682,555. The capital increase is expected to be finalized shortly.
The schemes are charged continuously to the P&L and the purchase of treasury shares will have no effect on the P&L.
Financial guidance
The content of this release will have no influence on the Lundbeck Group's financial guidance for 2012 which was provided on 8 February 2012 in connection with the release of the financial results for 2011.
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Chief Specialist, Head of Investor Relations | Media Relations Manager |
| palo@lundbeck.com | mavk@lundbeck.com |
| +45 36 43 24 26 | +45 36 43 28 51 |
| Magnus Thorstholm Jensen | Simon Mehl Augustesen |
| Investor Relations Officer | International Media Specialist |
| matj@lundbeck.com | smeh@lundbeck.com |
| +45 36 43 38 16 | +45 36 43 49 80 |
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.